These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 3164987)

  • 21. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969).
    Espinoza AM; Chin NX; Novelli A; Neu HC
    Antimicrob Agents Chemother; 1988 May; 32(5):663-70. PubMed ID: 3293524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antibacterial activities of monobactams against fresh clinical isolates].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Fukayama S; Nishimura Y; Oda S; Tanaka S; Kato M; Sato K
    Jpn J Antibiot; 1988 Nov; 41(11):1600-22. PubMed ID: 3210297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of lomefloxacin (NY-198 or SC 47111).
    Shah PM; Müller S; Kipp J; Stille W
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):97S-101S. PubMed ID: 2791506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of action of lomefloxacin.
    Piddock LJ; Hall MC; Wise R
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1088-93. PubMed ID: 2168142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro evaluation of E-4695, a new fluoro-naphthyridine.
    Jones RN
    Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):188-94. PubMed ID: 1327787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.
    Chin NX; Neu HC
    Antimicrob Agents Chemother; 1983 Nov; 24(5):754-63. PubMed ID: 6229216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.
    Clarke AM; Zemcov SJ; Campbell ME
    J Antimicrob Chemother; 1985 Jan; 15(1):39-44. PubMed ID: 3156112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of sparfloxacin compared with those of five other quinolones.
    Cantón E; Pemán J; Jimenez MT; Ramón MS; Gobernado M
    Antimicrob Agents Chemother; 1992 Mar; 36(3):558-65. PubMed ID: 1320362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone.
    Chin NX; Brittain DC; Neu HC
    Antimicrob Agents Chemother; 1986 Apr; 29(4):675-80. PubMed ID: 3085584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1985 May; 15(5):551-8. PubMed ID: 3159712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The in-vitro activity of EN 272, a quinolone-7-carboxylic acid, in comparison with other quinolones.
    Neu HC
    J Antimicrob Chemother; 1985 Jul; 16(1):43-8. PubMed ID: 3862659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of CI-934 compared with ciprofloxacin, enoxacin, norfloxacin, and vancomycin.
    Floyd-Reising SA; Kelley SG; Hindler JA; Young LS
    Diagn Microbiol Infect Dis; 1987 Apr; 6(4):301-6. PubMed ID: 3472704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro evaluation of lomefloxacin activity in Colombia.
    Trujillo H; Mejia GI; Castrillon L; Gomez C
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):51S-52S. PubMed ID: 2791498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of PD 117596-2, a broad-spectrum difluoroquinolone.
    Neu HC; Chin NX
    Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):644-50. PubMed ID: 2506029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency and expression of mutational resistance to the 4-quinolone antibacterials.
    Smith JT
    Scand J Infect Dis Suppl; 1986; 49():115-23. PubMed ID: 3547618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.
    Smith SM
    Antimicrob Agents Chemother; 1986 Feb; 29(2):325-6. PubMed ID: 2940966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin.
    Knapp JS; Hale JA; Neal SW; Wintersheid K; Rice RJ; Whittington WL
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2442-5. PubMed ID: 8585723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
    Stamm JM; Hanson CW; Chu DT; Bailer R; Vojtko C; Fernandes PB
    Antimicrob Agents Chemother; 1986 Feb; 29(2):193-200. PubMed ID: 3087274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid.
    King A; Shannon K; Slegg J; Phillips I
    J Antimicrob Chemother; 1986 Aug; 18(2):163-9. PubMed ID: 3463557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.